Cargando…

Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway

BACKGROUND: It has been demonstrated that berberine (BBR), a kind of alkaloid derived from Chinese herbal medicine, has multiple pharmacological effects on human’s diseases including anti-atherosclerosis action. However, although the previous studies showed that the beneficial impact of BBR on ather...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Chun-Yan, Shi, Xiao-Yun, Wu, Ya-Ru, Zhang, Yue, Yao, Yu-Hong, Qu, Hui-Lin, Zhang, Wei, Guo, Yuan-Lin, Xu, Rui-Xia, Li, Jian-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576642/
https://www.ncbi.nlm.nih.gov/pubmed/34790723
http://dx.doi.org/10.21037/atm-20-8106
_version_ 1784595916401934336
author Ma, Chun-Yan
Shi, Xiao-Yun
Wu, Ya-Ru
Zhang, Yue
Yao, Yu-Hong
Qu, Hui-Lin
Zhang, Wei
Guo, Yuan-Lin
Xu, Rui-Xia
Li, Jian-Jun
author_facet Ma, Chun-Yan
Shi, Xiao-Yun
Wu, Ya-Ru
Zhang, Yue
Yao, Yu-Hong
Qu, Hui-Lin
Zhang, Wei
Guo, Yuan-Lin
Xu, Rui-Xia
Li, Jian-Jun
author_sort Ma, Chun-Yan
collection PubMed
description BACKGROUND: It has been demonstrated that berberine (BBR), a kind of alkaloid derived from Chinese herbal medicine, has multiple pharmacological effects on human’s diseases including anti-atherosclerosis action. However, although the previous studies showed that the beneficial impact of BBR on atherosclerosis might be associated with proprotein convertase subtilisin/kexin type 9 (PCSK9), the exact underlying mechanism are not fully determined. The present study aimed to investigate potential mechanisms of anti-atherosclerosis by BBR using ApoE(-/-) mice. METHODS: The eight-week mice were divided into five groups: group 1 (wild type C57BL/6J mice with normal diet), group 2 (ApoE(-/-) mice with normal diet), group 3 [ApoE(-/-) mice with high-fat diet (HFD)], group 4 (ApoE(-/-) mice with HFD, and treatment with low dose BBR of 50 mg/kg/d), and group 5 (ApoE(-/-) mice with HFD, and treatment with high dose BBR of 100 mg/kg/d). After a 16-week treatment, the blood sample, aorta and liver were collected for lipid analysis, hematoxylin-eosin (HE) or oil red O staining, and Western blotting respectively. Besides, HepG2 Cells were cultured and treated with different concentrations of BBR (0, 5, 25 and 50 µg/mL) for 24 hours. Subsequently, cells were collected for real-time PCR or western blotting assays. Finally, the expression levels of PCSK9, LDL receptor (LDLR), ATP-binding cassette transporter A1 (ABCA1), ATP-binding cassette transporter G1 (ABCG1), and scavenger receptor class B type I (SR-BI) were examined. RESULTS: Fifty mg/kg/d and 100 mg/kg/d of BBR decreased total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) cholesterol (LDL-C), and increased high-density lipoprotein cholesterol (HDL-C) level. Moreover, BBR reduced aorta atherosclerotic plaque, and ameliorated lipid deposition in ApoE(-/-) mice fed with HFD. Finally, in vitro study showed that BBR promoted intracellular cholesterol efflux, up-regulated LDLR and down-regulated PCSK9 expression via the ERK1/2 pathway in cultured HepG2 cells. CONCLUSIONS: Data indicated that BBR significantly attenuated lipid disorder, reduced aortic plaque formation, and alleviated hepatic lipid accumulation in ApoE(-/-) mice fed with HFD, which was associated with down-regulation of PCSK9 through ERK1/2 pathway.
format Online
Article
Text
id pubmed-8576642
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-85766422021-11-16 Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway Ma, Chun-Yan Shi, Xiao-Yun Wu, Ya-Ru Zhang, Yue Yao, Yu-Hong Qu, Hui-Lin Zhang, Wei Guo, Yuan-Lin Xu, Rui-Xia Li, Jian-Jun Ann Transl Med Original Article BACKGROUND: It has been demonstrated that berberine (BBR), a kind of alkaloid derived from Chinese herbal medicine, has multiple pharmacological effects on human’s diseases including anti-atherosclerosis action. However, although the previous studies showed that the beneficial impact of BBR on atherosclerosis might be associated with proprotein convertase subtilisin/kexin type 9 (PCSK9), the exact underlying mechanism are not fully determined. The present study aimed to investigate potential mechanisms of anti-atherosclerosis by BBR using ApoE(-/-) mice. METHODS: The eight-week mice were divided into five groups: group 1 (wild type C57BL/6J mice with normal diet), group 2 (ApoE(-/-) mice with normal diet), group 3 [ApoE(-/-) mice with high-fat diet (HFD)], group 4 (ApoE(-/-) mice with HFD, and treatment with low dose BBR of 50 mg/kg/d), and group 5 (ApoE(-/-) mice with HFD, and treatment with high dose BBR of 100 mg/kg/d). After a 16-week treatment, the blood sample, aorta and liver were collected for lipid analysis, hematoxylin-eosin (HE) or oil red O staining, and Western blotting respectively. Besides, HepG2 Cells were cultured and treated with different concentrations of BBR (0, 5, 25 and 50 µg/mL) for 24 hours. Subsequently, cells were collected for real-time PCR or western blotting assays. Finally, the expression levels of PCSK9, LDL receptor (LDLR), ATP-binding cassette transporter A1 (ABCA1), ATP-binding cassette transporter G1 (ABCG1), and scavenger receptor class B type I (SR-BI) were examined. RESULTS: Fifty mg/kg/d and 100 mg/kg/d of BBR decreased total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) cholesterol (LDL-C), and increased high-density lipoprotein cholesterol (HDL-C) level. Moreover, BBR reduced aorta atherosclerotic plaque, and ameliorated lipid deposition in ApoE(-/-) mice fed with HFD. Finally, in vitro study showed that BBR promoted intracellular cholesterol efflux, up-regulated LDLR and down-regulated PCSK9 expression via the ERK1/2 pathway in cultured HepG2 cells. CONCLUSIONS: Data indicated that BBR significantly attenuated lipid disorder, reduced aortic plaque formation, and alleviated hepatic lipid accumulation in ApoE(-/-) mice fed with HFD, which was associated with down-regulation of PCSK9 through ERK1/2 pathway. AME Publishing Company 2021-10 /pmc/articles/PMC8576642/ /pubmed/34790723 http://dx.doi.org/10.21037/atm-20-8106 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Ma, Chun-Yan
Shi, Xiao-Yun
Wu, Ya-Ru
Zhang, Yue
Yao, Yu-Hong
Qu, Hui-Lin
Zhang, Wei
Guo, Yuan-Lin
Xu, Rui-Xia
Li, Jian-Jun
Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway
title Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway
title_full Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway
title_fullStr Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway
title_full_unstemmed Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway
title_short Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway
title_sort berberine attenuates atherosclerotic lesions and hepatic steatosis in apoe(-/-) mice by down-regulating pcsk9 via erk1/2 pathway
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576642/
https://www.ncbi.nlm.nih.gov/pubmed/34790723
http://dx.doi.org/10.21037/atm-20-8106
work_keys_str_mv AT machunyan berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway
AT shixiaoyun berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway
AT wuyaru berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway
AT zhangyue berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway
AT yaoyuhong berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway
AT quhuilin berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway
AT zhangwei berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway
AT guoyuanlin berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway
AT xuruixia berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway
AT lijianjun berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway